Thoratec Corp. said an interim analysis of a Phase III trial of its HeartMate II showed that the device is statistically better than its other cardiac pump in treating patients who are ineligible for a transplant. The company plans to seek premarket approval from the FDA in the first half of next year to sell HeartMate II as a destination treatment.

Full Story:

Related Summaries